glp-1 cognitive benefits Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine An analysis on the role

A family of cAMP-binding proteins that directly activate Rap1

doi:10.1080/01443615.2024.2381569

65,66 A network meta-analysis ranked SEMA 0.4 mg first in the resolution of MASH among alternative treatments [surface under the cumulative ranking (SUCRA) = 0.89], higher than liraglutide (SUCRA = 0.84) and resmetirom (SUCRA = 0.44)

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, et al

Georgina Glenn May 19th 2026 Georgina Glenn April 30th 2026 Georgina Glenn March 23rd 2026

Standard practice includes: Baseline thyroid function tests (TSH and free T4) before initiating GLP-1 therapy Repeat testing at 812 weeks after starting treatment or after dose escalation Regular monitoring every 36 months during active weight loss Return to annual monitoring once weight is stable and thyroid function remains consistent Adjustments to levothyroxine dosing may be necessary as weight changes